- Home
- AMST vs BCDA Comparison
AMST vs BCDA Comparison
Compare AMST & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- BCDA
- Stock Information
- Founded
- AMST 2017
- BCDA N/A
- Country
- AMST United States
- BCDA United States
- Employees
- AMST N/A
- BCDA N/A
- Industry
- AMST Computer Software: Prepackaged Software
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- AMST Technology
- BCDA Health Care
- Exchange
- AMST Nasdaq
- BCDA Nasdaq
- Market Cap
- AMST 7.4M
- BCDA 7.9M
- IPO Year
- AMST 2020
- BCDA N/A
- Fundamental
- Price
- AMST $3.30
- BCDA $2.84
- Analyst Decision
- AMST
- BCDA Strong Buy
- Analyst Count
- AMST 0
- BCDA 1
- Target Price
- AMST N/A
- BCDA $25.00
- AVG Volume (30 Days)
- AMST 33.6K
- BCDA 55.7K
- Earning Date
- AMST 02-10-2025
- BCDA 03-26-2025
- Dividend Yield
- AMST N/A
- BCDA N/A
- EPS Growth
- AMST N/A
- BCDA N/A
- EPS
- AMST N/A
- BCDA N/A
- Revenue
- AMST $86,115.00
- BCDA $71,000.00
- Revenue This Year
- AMST N/A
- BCDA N/A
- Revenue Next Year
- AMST N/A
- BCDA N/A
- P/E Ratio
- AMST N/A
- BCDA N/A
- Revenue Growth
- AMST N/A
- BCDA N/A
- 52 Week Low
- AMST $1.85
- BCDA $1.63
- 52 Week High
- AMST $6.27
- BCDA $8.85
- Technical
- Relative Strength Index (RSI)
- AMST 45.99
- BCDA 67.71
- Support Level
- AMST $3.16
- BCDA $2.27
- Resistance Level
- AMST $3.60
- BCDA $2.78
- Average True Range (ATR)
- AMST 0.20
- BCDA 0.26
- MACD
- AMST 0.00
- BCDA 0.04
- Stochastic Oscillator
- AMST 33.03
- BCDA 86.90
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).